Infections and inflammatory bowel disease: Challenges in Asia

Journal of Digestive Diseases

Volumn 14, Issue 11, 2013, Pages 567-573

  Ng, Siew C ^a   Chan, Francis Kl ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clostridium difficile; Cytomegalovirus; Infection; Inflammatory bowel disease; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; LIVE VACCINE; PLACEBO; TUBERCULOSTATIC AGENT;

ARTICLE; ASIA; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON RESECTION; COLON ULCER; CROHN DISEASE; CYTOMEGALOVIRUS; ENTERITIS; HEPATITIS B; HUMAN; ILEUM DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INTESTINE INFARCTION; INTESTINE INFECTION; INTESTINE TUBERCULOSIS; MORTALITY; PRIORITY JOURNAL; SALMONELLA; TUBERCULOSIS; YERSINIA;

CLOSTRIDIUM DIFFICILE; CYTOMEGALOVIRUS; INFECTION; INFLAMMATORY BOWEL DISEASE; TUBERCULOSIS;

ASIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; INFLAMMATORY BOWEL DISEASES; MASS SCREENING; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS, GASTROINTESTINAL;

EID: 84884921190     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12091     Document Type: Article

References (47)

1. Ng SC, Tang W, Ching JY etal; Asia-Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. Gastroenterology 2013; 145: 158-65.e2.
2. Colombel JF, Loftus EV Jr, Tremaine WJ etal. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
3. Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol 2009; 104: 1003-1012.
4. Isbister WH, Hubler M. Inflammatory bowel disease in Saudi Arabia: presentation and initial management. J Gastroenterol Hepatol 1998; 13: 1119-1124.
5. Lee YJ, Yang SK, Byeon JS etal. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy 2006; 38: 592-597.
6. Makharia GK, Srivastava S, Das P etal. Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis. Am J Gastroenterol 2010; 105: 642-651.
7. Ibrahim M, Osoba AO. Abdominal tuberculosis. On-going challenge to gastroenterologists. Saudi Med J 2005; 26: 274-280.
8. Boudiaf M, Zidi SH, Soyer P etal. Tuberculous colitis mimicking Crohn's disease: utility of computed tomography in the differentiation. Eur Radiol 1998; 8: 1221-1223.
9. Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007; 25: 1373-1388.
10. Amarapurkar DN, Patel ND, Amarapurkar AD, Agal S, Baigal R, Gupte P. Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn's disease. J Assoc Physicians India 2004; 52: 863-867.
11. Li Y, Zhang LF, Liu XQ etal. The role of in vitro interferon γ-release assay in differentiating intestinal tuberculosis from Crohn's disease in China. J Crohns Colitis 2012; 6: 317-323.
12. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344.
13. Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 2013; 19: 194-204.
14. Issa M, Vijayapal A, Graham MB etal. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-351.
15. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264.
16. Ben-Horin S, Margalit M, Bossuyt P etal; European Crohn's and Colitis Organization (ECCO). Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-987.
17. Rahier JF, Ben-Horin S, Chowers Y etal; European Crohn's and Colitis Organization (ECCO). European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
18. Ben-Horin S, Margalit M, Bossuyt P etal; European Crohn's and Colitis Organization (ECCO). Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010; 4: 194-198.
19. Teasley DG, Gerding DN, Olson MM etal. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043-1046.
20. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
21. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508.
22. van Nood E, Vrieze A, Nieuwdorp M etal. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
23. Cottone M, Pietrosi G, Martorana G etal. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 773-775.
24. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2857-2865.
25. Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis 2012; 44: 541-548.
26. Toruner M, Loftus EV Jr, Harmsen WS etal. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
27. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 2013; 48: 595-600.
28. Caspersen S, Elkjaer M, Riis L etal. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-1217; quiz 1176.
29. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268-1276.
30. Lichtenstein G, Cohen RD, Feagan BG etal. Risk factors for serious infections in patients receiving infliximab and other crohn's disease therapies: TREAT™ registry data. Gastroenterology 2010; 5 (Suppl 1): S475.
31. Keane J, Gershon S, Wise RP etal. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
32. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
33. Schreiber S, Khaliq-Kareemi M, Lawrance IC etal; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250.
34. Tubach F, Salmon-Céron D, Ravaud P, Mariette X; RATIO Study Group. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapy. Joint Bone Spine 2005; 72: 456-460.
35. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V etal; BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
36. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
37. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 925-932.
38. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105: 1231-1238.
39. Hsu C, Hsiung CA, Su IJ etal. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-853.
40. Lau GK, Yiu HH, Fong DY etal. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749.
41. Loras C, Gisbert JP, Mínguez M etal; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.
42. Papay P, Eser A, Winkler S etal. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 84-90.
43. Papay P, Eser A, Winkler S etal. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest 2011; 41: 1071-1076.
44. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 19-30.
45. Ooi CJ, Fock KM, Makharia GK etal; Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 453-468.
46. Leung WK, Ng SC, Chow DK etal; Hong Kong IBD Society. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J 2013; 19: 61-68.
47. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.